Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095412 | 0.89 | DRD4 (0.50) | DRD4MAPTALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL6096282 | 0.75 | DRD4 (0.65) | DRD4MAPTALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL6095533 | 0.74 | DRD4 (0.56) | DRD4ALDH1A1HTR1AABCB11ADRA2A | |
| SCHEMBL6095618 | 0.70 | CACNA1G (0.43) | DRD4MAPTSMN1; SMN2TSHRNPSR1 | |
| SCHEMBL20063235 | 0.69 | PHGDH (0.85) | PHGDHLMNAMEN1KMT2A | |
| SCHEMBL2422735 | 0.69 | PHGDH (0.64) | PHGDHADRA1AKCNH2 | |
| SCHEMBL28226906 | 0.69 | ALDH1A1 (0.77) | MAPTALDH1A1SMN1; SMN2TSHRNPSR1 | |
| SCHEMBL18658152 | 0.68 | HTT (0.57) | DRD4ALDH1A1HTR1AKCNH2LMNA | |
| SCHEMBL23964164 | 0.68 | DRD4 (0.68) | DRD4HTR1AKCNH2GAAADRA2C | |
| SCHEMBL11914802 | 0.67 | ALDH1A1 (0.60) | MAPTALDH1A1SMN1; SMN2TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030150-B2 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-04-18 | — | — | US | claimed |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2003-06-26 | — | — | US | claimed |
| WO-2002092575-A1 | BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF | TRIMERIS, INC. (US) | 2002-11-21 | — | — | WO | claimed |
| US-20060142365-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-06-29 | — | — | US | disclosed |
| US-7030150-B2 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-04-18 | — | — | US | disclosed |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142365-A1 | Benzimidazole compounds and antiviral uses thereof | MAVS, ZC3HAV1, TIMM13 | DRD4 1827/4885MAPT 4679/4885ALDH1A1 1618/4885 |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | MAVS, ZC3HAV1, TIMM13 | DRD4 1827/4885MAPT 4679/4885ALDH1A1 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.